Cataract inhibitors: Present needs and future challenges.

Area of Science:

• Ophthalmology
• Surgical Innovation
• Drug Development

Background:

• Cataracts are a leading cause of blindness globally, often requiring lens replacement surgery.
• Posterior capsular opacification (PCO) is a common complication after cataract surgery, necessitating further treatment like laser capsulotomy.
• Novel therapies targeting aldose reductase are emerging to prevent PCO and its associated complications.

Purpose of the Study:

• To determine if cataract surgeons perceive an unmet need for preventative PCO therapies.
• To assess surgeons' willingness to prescribe and adopt novel PCO therapies.
• To understand surgeons' views on the benefits and barriers to adopting new PCO treatments.

Main Methods:

• An online questionnaire was distributed to adult, pediatric, and veterinary cataract surgeons.
• 161 surgeon responses were collected and analyzed to gather perspectives on preventative PCO therapy.
• Data on perceived needs, interest, benefits, and obstacles were compiled.

Main Results:

• A significant majority of surgeons across all specialties believe there is an unmet need for preventative PCO therapy.
• Over 95% of surgeons expressed strong interest in integrating preventative PCO therapy into their surgical protocols.
• Key perceived benefits include improved visual outcomes and avoiding laser procedures, while reimbursement and safety are noted obstacles.

Conclusions:

• Cataract surgeons strongly support the development of novel, preventative PCO therapies.
• Clinical trials are crucial for establishing the safety and efficacy of these emerging treatments.
• Preventative PCO therapy could enhance outcomes, particularly with premium intraocular lenses and in resource-limited settings.